FMC63 is an IgG2a mouse monoclonal antibody specific for CD19, which is a target for the immunotherapy of B lineage leukaemias and lymphomas. FMC63 scFv is the most commonly used ectodomain component of CD19-specific CARs. So far, most of reported CART19 trials contain the anti-CD19 scFv derived from FMC63, including the two FDA-approved CARs Kymriah and Yescarta.Anti-fmc63 scFv antibody can specifically bind to the antigen recognition epitope of fmc63 scFv on anti-CD19 car, and it shows high specificity and sensitivity,it's used to detect the expression of fmc63 scFv derived car.
